Managers / Q2 2025 · view latest →
Propel Bio Management, LLC
CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629
Summary
Propel Bio Management, LLC reported $82M in U.S.-listed holdings across 16 positions for Q2 2025.
The portfolio is heavily concentrated: PAGP alone accounts for 30.0% of reported value.
Compared with Q1 2025, the fund opened 2 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 68.9% · $57M
- Ltd Part · 30.0% · $25M
- Other · 1.1% · $919,079
Quarter-over-Quarter Changes full breakdown →
vs Q1 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CAPRCAPRICOR THERAPEUTICS INC | NEW | +70.0K | 70.0K | +$695,100 | $695,100 |
| WTS - Achieve Life Sci | NEW | +3.70M | 3.70M | +$13,687 | $13,687 |
| ACHVACHIEVE LIFE SCIENCES INC | ADDED | +3.70M | 6.15M | +$7M | $14M |
| MDGLMADRIGAL PHARMACEUTICALS | SOLD OUT | −30.0K | 0 | −$10M | $0 |
| AVIDITY BIOSCIENCES INC | SOLD OUT | −178.5K | 0 | −$5M | $0 |
| SNDXSYNDAX PHARMACEUTICALS IN | SOLD OUT | −183.3K | 0 | −$2M | $0 |
| CMPXCOMPASS THERAPEUTICS INC | SOLD OUT | −228.3K | 0 | −$433,802 | $0 |
| ABEOABEONA THERAPEUTICS INC | ADDED | +350.0K | 974.0K | +$3M | $6M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | PAGPPLAINS GP HOLDINGS LP-CLhistory → | COMM | 30.01% | $25M | 1.27M |
| 2 | ACHVACHIEVE LIFE SCIENCES INChistory → | COMM | 16.88% | $14M | 6.15M |
| 3 | AKROAKERO THERAPEUTICS INChistory → | COMM | 14.82% | $12M | 228.9K |
| 4 | PHATPHATHOM PHARMACEUTICALS Ihistory → | COMM | 10.74% | $9M | 922.9K |
| 5 | ABEOABEONA THERAPEUTICS INChistory → | COMM | 6.71% | $6M | 974.0K |
| 6 | APLTAPPLIED THERAPEUTICS INChistory → | COMM | 4.26% | $4M | 11.29M |
| 7 | MISTMILESTONE PHARMACEUTICALShistory → | COMM | 4.22% | $3M | 1.79M |
| 8 | DCTHDELCATH SYSTEMS INChistory → | COMM | 3.73% | $3M | 226.1K |
| 9 | TCRXTSCAN THERAPEUTICS INChistory → | COMM | 3.67% | $3M | 2.09M |
| 10 | ZVRAZEVRA THERAPEUTICS INChistory → | COMM | 2.48% | $2M | 231.9K |
| 11 | CAPRCAPRICOR THERAPEUTICS INC | COMM | 0.84% | $695,100 | 70.0K |
| 12 | MAAT PHARMA SACA | COMM | 0.55% | $452,069 | 94.2K |
| 13 | ATHIRA PHARMA INC | COMM | 0.55% | $450,823 | 1.49M |
| 14 | EIGER BIOPHARMACEUTICALS | COMM | 0.51% | $423,000 | 146.4K |
| 15 | WTS - Achieve Life Sci | COMM | 0.02% | $13,687 | 3.70M |
| 16 | CHINOOK THERAPEUTICS | COMM | 0.00% | $2,500 | 79.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $159M | 38 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $117M | 20 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $100M | 16 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 16 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $86M | 18 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $101M | 21 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $172M | 21 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $154M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $172M | 29 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 34 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Simplify Asset Management Inc.028-20937
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.